Symptoms include greenish vomit, severe abdominal pain, and possibly bloody stools
Reconstitution Solution is available separately
At baseline, approximately two-thirds of participants across all groups had normal kidney function, defined as eGFRcre 90 mL/min/1.73 m2 (67.3%, 70.6%, and 69.7% in the semaglutide 7.2 mg, 2.4 mg, and placebo groups, respectively)
Epithalon Side Effects and Safety: The Clinical Picture What the research says on tolerability Across the studies reviewed in the 2025 International Journal of Molecular Sciences analysis and in earlier clinical work, Epithalon has demonstrated a favorable tolerability profile
This approval followed the STEP UP trial, a Phase 3b study published in The Lancet Diabetes & Endocrinology in 2025, which evaluated the 7.2 mg weekly dose in over 1,400 adults with obesity and without diabetes